The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma
2018; AMCP; Volume: 24; Issue: 4 Linguagem: Inglês
10.18553/jmcp.2018.24.4.335
ISSN2376-1032
AutoresElyse Swallow, Andrew Messali, Sameer R. Ghate, Evangeline McDonald, Emilie D. Duchesneau, José Ricardo Pérez,
Tópico(s)Health Systems, Economic Evaluations, Quality of Life
ResumoWhen considering optimal second-line treatments for metastatic renal cell carcinoma (mRCC), clinicians and payers seek to understand the relative clinical benefits and costs of treatment.
Referência(s)